Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.85 -0.6%	$5.73	$2.90 ▼ $11.16	$308.71M	0.58	3.23 million shs	189,150 shs
GDRX GoodRx	$5.01 +2.2%	$4.33	$3.68 ▼ $9.26	$1.78B	1.16	1.41 million shs	1,236 shs
LLY Eli Lilly and Company	$779.79 +0.0%	$779.41	$677.09 ▼ $972.53	$737.36B	0.41	3.67 million shs	64,458 shs
NVO Novo Nordisk A/S	$68.33 -1.0%	$69.32	$57.00 ▼ $145.99	$304.65B	0.66	7.21 million shs	123,058 shs
VKTX Viking Therapeutics	$26.06 -1.7%	$27.24	$18.92 ▼ $81.73	$2.92B	0.65	4.01 million shs	17,964 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+10.57%	-44.64%	-28.73%	-18.35%	-41.80%
GDRX GoodRx	+1.63%	+6.18%	+27.37%	+12.42%	-36.15%
LLY Eli Lilly and Company	+0.41%	+1.19%	+5.56%	-3.03%	-13.92%
NVO Novo Nordisk A/S	+0.82%	-1.07%	-3.28%	+1.56%	-51.62%
VKTX Viking Therapeutics	-0.08%	+6.60%	-1.78%	+10.83%	-50.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.2831 of 5 stars	3.5	1.0	0.0	0.0	2.9	1.7	0.6
GDRX GoodRx	3.022 of 5 stars	3.3	2.0	0.0	0.0	1.6	2.5	1.9
LLY Eli Lilly and Company	4.9816 of 5 stars	4.4	4.0	3.3	4.0	2.8	1.7	1.9
NVO Novo Nordisk A/S	4.6251 of 5 stars	4.1	5.0	2.5	0.0	1.8	0.0	3.1
VKTX Viking Therapeutics	4.1179 of 5 stars	4.5	1.0	0.0	4.7	1.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	3.00	Buy	$19.00	393.76% Upside
GDRX GoodRx	2.64	Moderate Buy	$6.55	30.70% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	29.73% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	63.92% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	234.41% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, GDRX, ALT, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $5.25
5/9/2025	GDRX GoodRx	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $5.00
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00
5/1/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	15,605.56	N/A	N/A	$1.74 per share	2.21
GDRX GoodRx	$792.32M	2.26	$0.33 per share	15.40	$1.89 per share	2.65
LLY Eli Lilly and Company	$45.04B	16.41	$14.31 per share	54.48	$15.03 per share	51.88
NVO Novo Nordisk A/S	$42.12B	7.24	$3.89 per share	17.56	$4.66 per share	14.66
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
GDRX GoodRx	$16.39M	$0.08	62.26	27.82	2.18	3.57%	7.85%	3.91%	8/6/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	63.31	25.06	1.13	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.19	14.66	1.22	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest LLY, NVO, GDRX, ALT, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/7/2025	Q1 2025	GDRX GoodRx	$0.04	$0.09	+$0.05	$0.03	$202.25 million	$202.97 million
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.77%	N/A	48.82%	11 Years
NVO Novo Nordisk A/S	$1.64	2.40%	N/A	48.52%	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest LLY, NVO, GDRX, ALT, and VKTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
GDRX GoodRx	0.74	5.23	5.23
LLY Eli Lilly and Company	2.18	1.37	1.06
NVO Novo Nordisk A/S	0.70	0.74	0.56
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
GDRX GoodRx	63.77%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
GDRX GoodRx	4.17%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
GDRX GoodRx	950	357.17 million	342.28 million	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.41 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

LLY, NVO, GDRX, ALT, and VKTX Headlines

Recent News About These Companies

Got $200? 2 Biotech Stocks to Buy and Hold Forever

2 hours ago | fool.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Brokerages

July 1 at 2:30 AM | marketbeat.com

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

...

June 29 at 8:36 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 27, 2025 | zacks.com

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

June 27, 2025 | americanbankingnews.com

Why This Weight Loss Drug Company's Stock Surged Today

June 26, 2025 | fool.com

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

June 26, 2025 | zacks.com

VKTX Viking Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Holdings Increased by International Assets Investment Management LLC

June 26, 2025 | marketbeat.com

Oppenheimer & Co. Inc. Acquires 23,481 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 26, 2025 | marketbeat.com

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

June 25, 2025 | msn.com

Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright

June 25, 2025 | marketbeat.com

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

June 25, 2025 | prnewswire.com

My 5 Favorite Dirt Cheap Stocks to Buy Right Now

June 24, 2025 | fool.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8% - Here's Why

June 23, 2025 | marketbeat.com

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

June 21, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

June 20, 2025 | msn.com

Institute for Wealth Management LLC. Purchases 9,735 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 19, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 18, 2025 | marketbeat.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

June 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!

LLY, NVO, GDRX, ALT, and VKTX Company Descriptions

Altimmune NASDAQ:ALT

$3.85 -0.02 (-0.57%)

As of 09:35 AM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

GoodRx NASDAQ:GDRX

$5.01 +0.11 (+2.20%)

As of 09:35 AM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Eli Lilly and Company NYSE:LLY

$779.79 +0.26 (+0.03%)

As of 09:35 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$68.33 -0.69 (-1.00%)

As of 09:35 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics NASDAQ:VKTX

$26.06 -0.44 (-1.65%)

As of 09:35 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, GDRX, ALT, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, GDRX, ALT, and VKTX Earnings

Compare Dividends

Latest LLY, NVO, GDRX, ALT, and VKTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, GDRX, ALT, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, GDRX, ALT, and VKTX Company Descriptions

Altimmune NASDAQ:ALT

GoodRx NASDAQ:GDRX

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools